Vivaldi Coelho Rogerio, a director at Crinetics Pharmaceuticals (NASDAQ: CRNX), sold a total of 5,000 shares of the company's common stock on March 12, 2026, in two separate transactions executed under an established trading plan.
The larger of the two trades involved 4,477 shares sold at a weighted average price of $36.08, producing proceeds of $161,530. Traded prices in that block ranged from $35.65 to $36.53. The smaller transaction comprised 523 shares sold at a weighted average price of $36.77, yielding $19,229, with prices in that tranche spanning $36.69 to $36.89. Combined, the two transactions amounted to $180,760 in stock sold.
Following these dispositions, Mr. Coelho Rogerio retains direct ownership of 16,300 Crinetics shares. The director's sales were carried out automatically under a Rule 10b5-1 plan adopted on December 11, 2025, indicating the trades were pre-scheduled rather than discretionary at the time of execution.
At the time of reporting, Crinetics' common stock is trading at $37.49, representing an approximate year-to-date decline of 19%. Despite the pullback, analysts' published price targets for the company span from $55 to $97, reflecting differing assessments of the company's longer-term value.
Separately, the company released financial results for the fourth quarter of 2025 that outperformed consensus projections. Reported earnings per share were -$1.29, beating the forecasted -$1.34. Revenue for the quarter came in at $6.1 million versus an anticipated $4.0 million.
Institutional coverage also saw a change in target pricing: Citizens lowered its price target for Crinetics from $105 to $96 while retaining a Market Outperform rating. In its commentary, the firm cited early launch metrics for Palsonify as an encouraging signal for uptake in the acromegaly market. Surveyed physicians indicated expected adoption rates in the 20% to 30% range, a level Citizens says corresponds to a potential U.S. market between $670 million and $1 billion.
In addition to operating results and analyst commentary, financial-health indicators highlighted in market research note that Crinetics holds more cash than debt. An InvestingPro analysis referenced a strong current ratio of 12.32, a measure that suggests short-term liquidity well in excess of near-term liabilities. The Pro Research Report for CRNX and more than 1,400 other U.S. stocks is available for investors seeking deeper analysis.
Investors reviewing the director sale, recent earnings beat and analyst price targets may interpret these datapoints in several ways. The 10b5-1 mechanism frames the share disposals as pre-planned rather than opportunistic, while the company's reported quarter and forward-looking adoption metrics for Palsonify are contributing to continued analyst interest and varied price target expectations.
For market participants focused on the healthcare and biotechnology sectors, Crinetics' liquidity position, launch performance indicators and management trading activity may all factor into ongoing evaluations of the company's prospects.